title: Plasma visfatin concentrations in severely obese subjects are increased after intestinal bypass.
abstract: OBJECTIVE
  Visfatin has shown to be increased in obesity and in type 2 diabetes. The aim of this study was to determine the change in plasma visfatin in severely obese (SO) persons after weight loss following bariatric surgery in relation to glucose concentration.
  
  
  METHODS
  Visfatin and leptin were studied in 53 SO persons (BMI, 54.4 +/- 6.8 kg/m(2)) before and 7 months after bariatric surgery and in 28 healthy persons (BMI, 26.8 +/- 3.8 kg/m(2)). All of the patients underwent bariatric surgery with biliopancreatic diversion or gastric bypass.
  
  
  RESULTS
  The pre-surgery levels of visfatin in the SO group were greater than in the control group (55.9 +/- 39.9 vs. 42.9 +/- 16.6 ng/mL, p = 0.024). This increase was significant in the SO group with impaired fasting glucose (63.4 +/- 36.6 ng/mL) and diabetes (60.0 +/- 46.0 ng/mL). SO patients with normal fasting glucose had similar levels of visfatin to the controls. Seven months after surgery, visfatin levels were significantly increased (84.8 +/- 32.8 ng/mL, p < 0.001). This increase was independent of the pre-surgical glucose levels. The type of bariatric surgery had no influence on visfatin levels. Post-surgical visfatin was significantly correlated with the post-surgery plasma concentrations of leptin (r = 0.39, p = 0.014).
  
  
  CONCLUSIONS
  Plasma levels of visfatin in the SO group were increased but only when accompanied by high glucose levels, even in the range of impaired fasting glucose. Bariatric surgery causes an increase in visfatin, which is correlated mainly with the changes produced in the leptin concentration.
authors.affiliation: Fundación Instituto Mediterraneo para el Avance de la Biomedicina y la Investigación Biosanitaria (IMABIS), Málaga, Spain. edugf1@eresmas.com
authors.forename: Eduardo
authors.initials: E
authors.lastname: García-Fuentes
authors.forename: Jose M
authors.initials: JM
authors.lastname: García-Almeida
authors.forename: Juan
authors.initials: J
authors.lastname: García-Arnés
authors.forename: Sara
authors.initials: S
authors.lastname: García-Serrano
authors.forename: Jose
authors.initials: J
authors.lastname: Rivas-Marín
authors.forename: Jose L
authors.initials: JL
authors.lastname: Gallego-Perales
authors.forename: Gemma
authors.initials: G
authors.lastname: Rojo-Martínez
authors.forename: Lourdes
authors.initials: L
authors.lastname: Garrido-Sánchez
authors.forename: Francisco J
authors.initials: FJ
authors.lastname: Bermudez-Silva
authors.forename: Fernando
authors.initials: F
authors.lastname: Rodríguez de Fonseca
authors.forename: Federico
authors.initials: F
authors.lastname: Soriguer
mesh_terms: D000328:Adult; D005260:Female; D006801:Humans; D007581:Jejunoileal Bypass; D008297:Male; D008875:Middle Aged; D054409:Nicotinamide Phosphoribosyltransferase / Q000097:blood*; D009767:Obesity, Morbid / Q000175:diagnosis* / Q000601:surgery*; D016896:Treatment Outcome; D015431:Weight Loss
chemical_list: D054409:Nicotinamide Phosphoribosyltransferase